KRAS-G12C is a driver mutation detected in human NSCLC, and drugs targeting KRAS-G12C have been developed and approved for the treatment of advanced NSCLC with KRAS-G12C mutations [36]. Here, KRAS is linked to non-small cell lung carcinoma.